Regeneron Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

REGN Regeneron Pharmaceuticals Inc

REMX VanEck Rare Earth/Strategic Metals ETF

PYPL PayPal Holdings Inc

PWZ Invesco California AMT-Free Municipal Bond ETF

PVG Pretium Resources Inc

PTY PIMCO Corporate and Income Opportunity Fund

PTA COHEN & STEERS TAX-ADV PRD SEC AND INC

PSXP Phillips 66 Partners LP

PSX Phillips 66

PSK SPDR® ICE Preferred Securities ETF

Go

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today named 40 finalists in this year's Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school...(PR Newswire)

Over $3 Million to be Awarded in Oldest and Most Prestigious U.S. STEM Competition for High School Seniors Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today named 40 finalists in this year's Regeneron Science...(PR Newswire)

Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions (PR Newswire)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2021 financial and operating results on Friday, February 4, 2022, before the U.S. financial markets open. The Company will host a...(PR Newswire)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Ultragenyx Pharmaceutical Inc. today announced a license and collaboration agreement for Ultragenyx to clinically develop, commercialize and distribute Evkeeza(R) (evinacumab) in countries outside...(PR Newswire)

FinancialNewsMedia.com News Commentary - Alzheimer's disease is a degenerative, progressive ailment that attacks the brain's nerve cells, resulting in memory loss, behavioral changes as well as changes in thinking and language skills. During the...(PR Newswire)

Dupixent significantly improved skin clearance and reduced overall disease severity and itch in pivotal trial that met all primary and secondary endpoints Global regulatory filings planned in the coming months, starting with the U.S. by the end of...(PR Newswire)

Includes latest data for REGN5458, including in highest dose levels (200-800 mg) Among patients who responded across all dose groups (3-800 mg), there was a 90% probability of being event-free (i.e., alive without disease progression) 8 months from...(PR Newswire)

Dupixent significantly reduced severe asthma attacks and improved lung function and asthma control in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma Published results reinforce well-established safety profile of Dupixent (PR Newswire)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the H.C. Wainwright & Co. event - Unlocking the Full Potential of RNAi With World-Class Novel Target Identification: Regeneron Genomics and...(PR Newswire)

FinancialNewsMedia.com News Commentary - Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White fluid can leak from the affected region, necessitating treatment. The atopic dermis is...(PR Newswire)

FinancialNewsMedia.com News Commentary - Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White fluid can leak from the affected region, necessitating treatment. The atopic dermis is...(PR Newswire)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: -- Evercore ISI 4th Annual HealthCONx Conference at 9:15 a.m. ET on Tuesday, November 30, 2021 -- Piper Sandler 33rd Annual Healthcare Conference at...(PR Newswire)

DJSI World highlights the most sustainable companies around the world by industry Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been recognized as a global corporate responsibility leader through inclusion on the Dow Jones Sustainability World...(PR Newswire)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that its Board of Directors authorized a share repurchase program of up to $3 billion of the Company's outstanding common stock. "With the strength of our balance sheet and our business...(PR Newswire)

EC marketing authorization follows approvals in Japan, Australia and the UK Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has approved the casirivimab and imdevimab antibody cocktail, known as...(PR Newswire)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the casirivimab and imdevimab antibody cocktail, known...(PR Newswire)

Single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction previously reported during month 1 (PR Newswire)

-- Third quarter 2021 revenues increased 51% to $3.45 billion versus third quarter 2020 including $804 million attributable to REGEN-COV(R)(2) -- Third quarter 2021 EYLEA(R) U.S. net sales increased 12% versus third quarter 2020 to $1.47 billion (PR Newswire)